Cervical cancer subtype rising in some sub-populations

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new study reports that a type of cervical cancer that is less amenable to Pap testing is increasing in several subpopulations of women, pointing to the growing importance of human papillomavirus testing and vaccination. The study can be found here.

Overall trends in cervical cancer incidence have been driven by declines in squamous cell carcinoma, which account for the majority of cervical cancers. Most of the rest are adenocarcinomas, for which Pap testing is less sensitive.

While overall cervical cancer rates have been dropping for decades, cervical adenocarcinomas seem to have become more common in the past 20 to 30 years. But there has been limited reporting on recent trends.

To learn more, investigators led by Farhad Islami, analyzed recent cervical cancer incidence trends by histology and age in the U.S. They examined trends in squamous cell carcinoma and adenocarcinoma incidence rates in the U.S. by age group, race/ethnicity, and stage at diagnosis using data from the U.S. Cancer Statistics Incidence Analytic Database.

They found squamous cell carcinoma incidence rates continued to decrease in all racial/ethnic groups except among non-Hispanic whites, in whom rates stopped dropping in the 2010s. For adenocarcinoma, after being stable between 1999 and 2002, incidence rates among non-Hispanic whites rose 1.3% per year during 2002–2015.

Those increases were driven by steeper increases in women ages 40 to 49, among whom cervical adenocarcinoma rates rose 4.4% per year since 2004, and women 50 to 59 years, among whom rates rose 5.5% per year since 2011. Adenocarcinoma incidence decreased in blacks and Hispanics during 1999–2015 and was stable in Asian/Pacific Islanders.

“Increasing or stabilized incidence trends for [adenocarcinoma] and attenuation of earlier declines for [squamous cell carcinoma] in several subpopulations underscore the importance of intensifying efforts to reverse the increasing trends and further reduce the burden of cervical cancer in the U.S.,” the study said.

The authors state that “more efforts are needed to increase screening utilization according to guidelines and appropriate follow-up of positive results” to further reduce the burden of cervical cancer.

They note that increasing the use of HPV testing may improve early detection of adenocarcinoma, but they also recommend research to further improve screening strategies to reduce overdiagnosis, which may be more common with HPV testing. HPV vaccination is an effective tool to prevent cervical cancer because virtually all these cancers are caused by HPV infection.

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login